
Using patient experience data to demonstrate the value of CAR-T cell therapies in clinical trials of hematological cancers
This paper examines the importance of:
- Patient input and experience data (PED) in understanding the impact of CAR-T cell therapy
- Opportunities and barriers in generating PED, emphasizing its importance in long-term follow-up
- Challenges in capturing patient perspectives for CAR-T treatments and potential solutions

